Coagulation and fibrinolytic activities in 2 siblings with beta(2)-glycoprotein I deficiency.

beta(2)-Glycoprotein I (beta(2)GPI) is a major antigen for antiphospholipid antibodies, and its multiple in vitro functions have been reported. This glycoprotein not only down-regulates thrombin formation by inhibiting contact activation or prothrombinase activity, but also up-regulates coagulation by reducing protein C anticoagulant activity. However, the in vivo roles of beta(2)GPI remain obscure. Coagulation and fibrinolytic characteristics were investigated in individuals with beta(2)GPI deficiency. An apparently healthy woman and her brother are homozygotes for beta(2)GPI deficiency. In these patients, Russell viper venom time was shortened (40.4 seconds; normal range, 47.8 +/- 4.95 seconds), but all markers of thrombin generation and fibrin turnover were within normal ranges. Exogenous activated protein C adequately prolonged the clotting time of the beta(2)GPI-deficient plasma, and euglobulin lysis time was also normal. Thus, elevated thrombin generation, enhancement of activated protein C response, and an altered fibrinolytic system were not found in congenitally beta(2)GPI-deficient plasma. (Blood. 2000;96:1594-1595)

[1]  B. Lentz,et al.  Characterization of β2-Glycoprotein I Binding to Phospholipid Membranes , 1998, Thrombosis and Haemostasis.

[2]  M. S. Rasmussen,et al.  Synchronized Inhibition of the Phospholipid Mediated Autoactivation of Factor XII in Plasma by β2-glycoprotein I and Anti-β2-glycoprotein I , 1995, Thrombosis and Haemostasis.

[3]  P. Hogg,et al.  Anticardiolipin Antibodies Block the Inhibition by β2-Glycoprotein I of the Factor Xa Generating Activity of Platelets , 1993, Thrombosis and Haemostasis.

[4]  T. Sumida,et al.  Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. , 1992, Journal of immunology.

[5]  R. Bertina,et al.  β2-Glycoprotein I Deficiency and the Risk of Thrombosis , 1992, Thrombosis and Haemostasis.

[6]  S. Ibbotson,et al.  Thrombin Activity by Intrinsic Activation of Plasma In-Vitro Accelerates with Increasing Age of the Donor , 1992, Thrombosis and Haemostasis.

[7]  M. Igarashi,et al.  Molecular definition of human β2-glycoprotein (α2-GPI) by cDNA cloning and inter-species differences of β2-GPI in alternation of anticardiolipin binding , 1991 .

[8]  Robert B Sim,et al.  Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. , 1991, The Biochemical journal.

[9]  T. Koike,et al.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease , 1990, The Lancet.

[10]  P. Bomans,et al.  Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I , 1986 .

[11]  J. Nimpf,et al.  Interaction of β2-Glycoprotein-I with Human Blood Platelets: Influence Upon the ADP-Induced Aggregation , 1985, Thrombosis and Haemostasis.

[12]  W. Kisiel,et al.  Factor X activating enzyme from Russell's viper venom: isolation and characterization. , 1976, Biochemistry.

[13]  J. Nishioka,et al.  β2-Glycoprotein I Modulates the Anticoagulant Activity of Activated Protein C on the Phospholipid Surface , 1996, Thrombosis and Haemostasis.